Ann: March 2014 NEWSLETTER , page-47

HT - not much further comment relating to your post about MZ, but I too think this is significant, as from their website it appears their KPI's are directly related to an ascending share price.

From the newsletter again.

Consequently we recently engaged the services of MZ Group, one of the world’s largest independent investor relations advisory firms. We view this appointment as important in increasing our exposure to the investor community in the US. MZ Group
has worked with a number of mid cap life science companies (mainly in the US), many of which experienced large increases in market capitalisation during 2013. MZ will assist us with developing and executing a comprehensive investor relations outreach program globally with a particular emphasis on North America.


Interesting that apart from their focus on North America, MZ have an Australian branch, but emphasis from POH via MZ is on North America further confirming a directional change to re-focus on the USA.

From MZ January 2014 newsletter.

MZ Adds Three New Clients to Growing Roster

MZ is pleased to announce the addition of three new clients, Phosphagenics Limited, Energous Corporation, and Loan Oak Acquisition Corporation who have chosen MZ to serve as their investor relations service provider. The MZ team will work closely with our clients’ management to establish an effective and targeted shareholder outreach campaign, which includes properly packaging their story, establishing the appropriate expectations, and providing consistent transparency into the business. By introducing key market participants, the overall goal of these efforts should lead to increased corporate visibility, greater shareholder diversification and a market multiple consistent with comparables, as well the company’s specific growth prospects.

Phosphagenics Limited (ASX: POH) (OTCQX: PPGNY) is commercializing drug
delivery applications based on its novel transdermal (drugs administered via
skin) TPM® – Targeted Penetration Matrix technology. TPM® is a patient
friendly and cost effective system used to deliver proven pharmaceutical and
nutraceutical products. The lead products advancing through clinical trials are
an oxymorphone and oxycodone matrix system for the relief of chronic pain. Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY). For more information, please visit www.phosphagenics.com.


I think we might finally get the global exposure we were all hoping the opioid patches would get. I'll be watching their web site closely.